

PRESS RELEASE

DIESSE ANNOUNCES A STRATEGIC PARTNERSHIP WITH GRIFOLS TO DEVELOP AND COMMERCIALIZE TESTS FOR BIOLOGIC DRUGS MONITORING

Siena, June 23 2021 – DIESSE Diagnostica Senese has signed a strategic agreement with Grifols for the development and commercialization of Grifols' Promonitor tests on DIESSE's Chorus analyzer.

Grifols, a leader in biological drug monitoring with its Promonitor test platform, offers a comprehensive test panel that can provide key information on drug bioavailability and immunogenicity in patients receiving biological therapy for the treatment of chronic inflammatory diseases and other indications.

Biologic drugs monitoring, along with clinical findings, ensures personalized treatment for each patient, contributing to valuable information that enables a customized approach. In addition, early information about potential reduced drug efficacy provides an early warning about the fact that the treatment regime may require modification.

DIESSE immunoassay analyzer Chorus TRIO with ready-to-use devices and a menu of more than 150 available tests is the ideal, reliable and simple solution for the assay of immunodiagnostic specialties without any waste of material thanks to its single test devices, made today even more flexible and effective in providing diagnostic information in a short time and with DIESSE quality.

The development of Promonitor tests on the Chorus automated system across Europe will improve the efficiency and ease of use while maintaining the high quality of results and improving overall patient management.

"We are very proud that Grifols has chosen us to include its Promonitor solution to monitor biologic drugs," states Luigi Nava, Commercial Operations Director of DIESSE. "New Promonitor tests for Chorus represent another milestone aligned with DIESSE's strategy called Diagnostics Evolution, pursuing the objective of offering continuous innovation and improving people's lives."

"Grifols is pleased to partner with DIESSE to provide its state-of-the-art Promonitor family of tests to measure both drug levels and anti-drug antibody levels to improve the care of patients and their well-being," says Guillermo Marco-Gardoqui, vice president, Global Clinical Diagnostics, Grifols.



Diagnostica Senese S.p.A.

www.diesse.it



This agreement confirms the importance of combining complementary knowledge in the world of Diagnostics. It will accelerate innovation and guarantee the consistency of solutions offered to diagnostic laboratories.

Diesse Diagnostica Senese SpA is an Italian company with integrated and entirely inhouse production of in vitro diagnostic systems. Its headquarters are in Siena. Since its foundation in 1980, the company has developed, produced and marketed innovative diagnostic systems primarily in the field of immunodiagnostics and automatic measurement of erythrocyte sedimentation rate (ESR). The company has a global presence in over 100 countries, three production sites and a research centre where the design and implementation of tests and new automated diagnostic detection tools meet Italian design and cutting-edge technology, making Diesse synonymous with "Diagnostics Evolution".

Grifols is a global healthcare company founded in Barcelona in 1909 committed to improving the health and well-being of people around the world. Its four divisions – Bioscience, Diagnostic, Hospital and Bio Supplies – develop, produce and market innovative solutions and services that are sold in more than 100 countries. Grifols, with more than 24,000 employees in 30 countries, is committed to a sustainable business model that sets the standard for continuous innovation, quality, safety and ethical leadership. For more information, please visit www.grifols.com.

DIESSE

Media Press Office:

Federica Casiraghi – DIESSE Diagnostica Senese

Tel. +39 342 9511925 – federicacasiraghi@diesse.it

Grifols

Media Press Office:

media@grifols.com

Tel. + 34 93 571 00 02